In a press release dated February 22, 2021, the European Patent Office indicates several changes made to Rules 19 and 143 EPC relating to the designation of inventors, taking into account the requirements of the GDPR and simplifying processing.

Read more ...

Earsc logo

During a webinar about Intellectual Property Rights in China and ASEAN countries hosted by China and South-East Asia IP SME Helpdesk on May 12, 2021, EARSC (European Association of Remote Sensing Companies) had the opportunity to learn from Vidon Group’s expertise.

Patrice VIDON was the keynote speaker sharing his knowledge about tips and best practice for SMEs of PARSEC accelerator program and European Association of Remote Sensing Companies (EARCS).

Download the presentation document here: PDF (1.6 Mo)

More information on the European Commission website



Sans titre  


The current health crisis does not prevent the long-awaited launch of the administrative procedure for invalidity and revocation in France.



The major innovation of the “PACTE” law on trademarks, came into force on 1 April 2020: with the creation of a "Cancellation" cell within the French Office, it is now possible to bring an action for a declaration of invalidity or revocation in the form of an administrative procedure. 

Read more ...

The EPO has announced a revision of fees which will enter into force on 1 April 2020. This revision involves main fees (filing fee, search fee, examination fee, grant fee) as well as annual fees.

It is possible to arrange advanced payment of fees in the coming weeks (annual fees, examination fee, grant fee) and pay before 31, March 2020 in order to benefit from the current rate.

Feel free to contact us, we are at your disposal to assist you in the management of your patent rights.


Specific exemption: a necessity for pharmaceutical trademarks?
Clinical trial, Marketing Authorization Application and genuine use of a trademark.



Should pharmaceutical trademarks benefit of a  specific exemption for demonstrating their genuine use ?




(Copyright free taken from data base

The Court of Justice of the European Union (CJEU) confronts its traditional case law to the particular frame of pharmaceutical trademarks’ genuine use appreciation.

Traditionally, case law established a relative tolerance to the condition of genuine use since the latter can be recognized for goods and services whose commercialization is not effective yet, but under way (CJEC, Ansul, March 11th, 2003, C-40/01).

Besides, it has already been specified that only obstacles that present a relation sufficiently direct with a trademark making impossible or unreasonable its useand that are independent from the will of the trademark’s owner can be qualified as “proper reasons” for non-use.   

Read more ...